TY - JOUR
T1 - Focal and Diffuse Chronic Central Serous Chorioretinopathy Treated With Half-Dose Photodynamic Therapy or Subthreshold Micropulse Laser: PLACE Trial Report No. 3
AU - van Rijssen, Thomas J.
AU - van Dijk, Elon H. C.
AU - Scholz, Paula
AU - Breukink, Myrte B.
AU - Blanco-Garavito, Rocio
AU - Souied, Eric H.
AU - Keunen, Jan E. E.
AU - MacLaren, Robert E.
AU - Querques, Giuseppe
AU - Fauser, Sascha
AU - Downes, Susan M.
AU - Hoyng, Carel B.
AU - Boon, Camiel J. F.
N1 - Copyright © 2019 Elsevier Inc. All rights reserved.
PY - 2019/9
Y1 - 2019/9
N2 - Purpose: To compare the outcome between high-density subthreshold micropulse laser (HSML) treatment and half-dose photodynamic therapy (PDT) in chronic central serous chorioretinopathy (cCSC) patients, subdivided based on either focal or diffuse leakage on fluorescein angiography (FA). Design: Retrospective analysis of multicenter randomized controlled trial data. Methods: Patients were treated with either half-dose PDT or HSML (both indocyanine green angiography–guided) and categorized in 2 groups, based on focal or diffuse leakage on FA. Clinical outcomes were evaluated at baseline and during follow-up. Results: In the focal leakage group (63 patients), both at first evaluation and at final visit, more PDT-treated than HSML-treated patients demonstrated a resolution of subretinal fluid (evaluation visit 1: 57% in the PDT group and 17% in the HSML group, P =.007; final visit: 75% and 38%, P =.012). In the diffuse leakage group (93 patients), both at first evaluation and at final visit, more PDT-treated than HSML-treated patients showed a resolution of subretinal fluid (evaluation visit: 1:48% in the PDT group and 16% in the HSML group, P =.002; final visit: 67% and 21%, P =.002). PDT-treated patients in the focal and diffuse leakage group had a higher retinal sensitivity increase, comparing baseline and final visit (+3.1 ± 3.1 dB vs +1.2 ± 4.0 dB, P =.048, and +2.7 ± 3.3 dB vs +1.0 ± 3.8 dB, P =.036, respectively). Only in the diffuse leakage group, the increase in ETDRS letters was higher in the PDT-treated group when comparing baseline and first evaluation visit (+4.4 ± 6.1 vs +0.9 ± 10.0, P =.049). Conclusions: Half-dose PDT is superior to HSML treatment in cCSC patients, regardless of the presence of focal or diffuse leakage on FA.
AB - Purpose: To compare the outcome between high-density subthreshold micropulse laser (HSML) treatment and half-dose photodynamic therapy (PDT) in chronic central serous chorioretinopathy (cCSC) patients, subdivided based on either focal or diffuse leakage on fluorescein angiography (FA). Design: Retrospective analysis of multicenter randomized controlled trial data. Methods: Patients were treated with either half-dose PDT or HSML (both indocyanine green angiography–guided) and categorized in 2 groups, based on focal or diffuse leakage on FA. Clinical outcomes were evaluated at baseline and during follow-up. Results: In the focal leakage group (63 patients), both at first evaluation and at final visit, more PDT-treated than HSML-treated patients demonstrated a resolution of subretinal fluid (evaluation visit 1: 57% in the PDT group and 17% in the HSML group, P =.007; final visit: 75% and 38%, P =.012). In the diffuse leakage group (93 patients), both at first evaluation and at final visit, more PDT-treated than HSML-treated patients showed a resolution of subretinal fluid (evaluation visit: 1:48% in the PDT group and 16% in the HSML group, P =.002; final visit: 67% and 21%, P =.002). PDT-treated patients in the focal and diffuse leakage group had a higher retinal sensitivity increase, comparing baseline and final visit (+3.1 ± 3.1 dB vs +1.2 ± 4.0 dB, P =.048, and +2.7 ± 3.3 dB vs +1.0 ± 3.8 dB, P =.036, respectively). Only in the diffuse leakage group, the increase in ETDRS letters was higher in the PDT-treated group when comparing baseline and first evaluation visit (+4.4 ± 6.1 vs +0.9 ± 10.0, P =.049). Conclusions: Half-dose PDT is superior to HSML treatment in cCSC patients, regardless of the presence of focal or diffuse leakage on FA.
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85067965886&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/30951686
U2 - https://doi.org/10.1016/j.ajo.2019.03.025
DO - https://doi.org/10.1016/j.ajo.2019.03.025
M3 - Article
C2 - 30951686
SN - 0002-9394
VL - 205
SP - 1
EP - 10
JO - American Journal of Ophthalmology
JF - American Journal of Ophthalmology
ER -